Mode
Text Size
Log in / Sign up
Phase 3 N=636 Randomized Triple-blind Prevention

Comparison Between Rectal & Sublingual Misoprostol Before Caesarian Section To Reduce Intra & Post-Operative Blood Loss

Postpartum Hemorrhage

Enrolled (actual)
636
Serious AEs
0.0%
Results posted
Jun 2014
Primary outcome: Primary: Intraoperative Blood Loss — 357.8; 641.7; 457.5 millilitres

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Misoprostol (Drug); Placebo (Other)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
Ain Shams University
Primary completion
Feb 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Intraoperative Blood Loss
357.8; 641.7; 457.5
SECONDARY
Need for Extra Ecbolics (Oxytocin).
209; 206; 204
SECONDARY
APGAR Score
6.5; 6.5; 6.5; 8.5; 8.5; 8.5
SECONDARY
Time to Resume Bowel Habits
15.1; 14.7; 14.5
SECONDARY
Need for Extra Analgesics
56; 62; 50
SECONDARY
Need for Postoperative Blood Transfusion
4; 10; 5
SECONDARY
Incidence of Wound Sepsis
3; 5; 4
SECONDARY
Incidence of Adverse Effects
44; 11; 26; 42; 11; 24

Summary

The aim of the work is to evaluate & compare the effectiveness of rectally administered PGE1 synthetic analogue (misoprostol) 400 microgram versus sublingually administered misoprostol before caesarean section to decrease blood loss during and after the operation.

Eligibility Criteria

Inclusion Criteria

  • Patients booked for elective cesarean section.
  • Singleton pregnancies. 3- Full term pregnancies (GA 37-42 weeks). 4- Patients with only previous one cesarian section

Exclusion Criteria

  • Primigravida.
  • Blood dyscrasias.
  • Large fibroids.
  • Multiple pregnancies.
  • Overdistended uterus eg. Hydramnios.
  • Pre-eclampsia.
  • Marked maternal anemia (Preoperative hemoglobin < 9 gm/dl).
  • Previous history of PPH.
  • Contraindications to prostaglandin therapy (e.g. history of severe bronchial asthma or allergy to misoprostol.
  • Placenta previa.
  • Contraindication to spinal anesthesia.
  • Previous myomectomy.
  • Previous two or more C.S.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02083107). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search